Vistagen Therapeutics Cuts 20% of Workforce to Extend Cash Runway into 2027
VTGN sits 35% above its 52-week low of $0.43 on light trading volume (0.1× avg).
Summary
Vistagen Therapeutics announced a 20% workforce reduction, effective March 5, 2026, as a measure to support cash management and its Palisade program clinical studies. This significant cost-cutting initiative is expected to extend the company's cash runway into 2027. This action directly addresses the severe financial challenges highlighted in the company's recent 10-Q filing, which disclosed substantial doubt about its ability to continue as a going concern, increased net losses, and a Nasdaq delisting threat. While indicating ongoing financial distress, the move is a proactive step to preserve capital and maintain operations. Traders will closely watch the company's progress on its clinical programs and any further financing efforts.
At the time of this announcement, VTGN was trading at $0.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.2M. The 52-week trading range was $0.43 to $5.14. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.